Fast Five Quiz: Myelodysplastic Syndrome Management

Emmanuel C. Besa, MD


May 12, 2021

The presence of a thrombopoietin level of 320 pg/mL or greater is associated with a good response to immunosuppressive therapy and high rates of progression-free survival. The National Institutes of Health developed an algorithm to predict response to immune-modulatory agents.

Although leukocytes that lack human antigen allele expression are present in some patients with MDS who have an underlying autoimmune component of the disease, their presence is not used to determine likelihood of response to immunosuppressive therapy. A 5q deletion is associated with a favorable prognosis in patients with MDS; however, lenalidomide is the drug of choice for patients with MDS and 5q deletion. Patients with TET2 mutation with wild-type ASXL1 are more likely to respond to treatment with hypomethylating agents.

Learn more about the workup of MDS.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: